Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.40 |
| ▸ | ITK | Q08881 | 8/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881388 | 1.00 | BTK (0.40) | BTKITKNTRK1PIK3CANEK1 | |
| SCHEMBL20846081 | 0.79 | MET (0.41) | BTKITKNTRK1PIK3CANEK1 | |
| SCHEMBL21988135 | 0.79 | GSK3B (0.51) | NTRK1PIK3CANEK1AAK1LRRK2 | |
| SCHEMBL31307016 | 0.79 | GSK3B (0.51) | NTRK1PIK3CANEK1AAK1LRRK2 | |
| SCHEMBL1043610 | 0.79 | BRD4 (0.43) | NTRK1PIK3CANEK1AAK1LRRK2 | |
| Hydrochloric Acid SCHEMBL21988060 | 0.78 | GSK3B (0.50) | NTRK1PIK3CANEK1AAK1LRRK2 | |
| Hydrochloric Acid SCHEMBL30279704 | 0.78 | GSK3B (0.50) | NTRK1PIK3CANEK1AAK1LRRK2 | |
| SCHEMBL7867182 | 0.76 | KMT2A (0.47) | NTRK1PIK3CANEK1AAK1LRRK2 | |
| SCHEMBL20561549 | 0.74 | NTRK1 (0.41) | ITKNTRK1PIK3CANEK1AAK1 | |
| SCHEMBL31635985 | 0.73 | AAK1 (0.37) | NTRK1PIK3CANEK1AAK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2024-09-05 | — | — | US | disclosed |
| CN-118043316-A | Factor XIIa inhibitors | 卢纳克治疗有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-4347578-A1 | FACTOR XIIA INHIBITORS | Lunac Therpeutics Ltd (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| WO-2022248883-A1 | FACTOR XIIA INHIBITORS | LUNAC THERAPEUTICS LTD (GB) | 2022-12-01 | — | — | WO | disclosed |
| CN-115103709-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2022-09-23 | — | — | CN | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021113682-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2016083816-A1 | N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171531-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BTK 3812/4885ITK 4073/4885NTRK1 4819/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | BTK 3747/4885ITK 4069/4885NTRK1 4809/4885 |
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | BTK 3812/4885ITK 4073/4885NTRK1 4819/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BTK 3747/4885ITK 4069/4885NTRK1 4809/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | BTK 3747/4885ITK 4069/4885NTRK1 4809/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BTK 3667/4885ITK 4208/4885NTRK1 4803/4885 |
| US-20240294498-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F7 | BTK 691/4885ITK 3826/4885NTRK1 4882/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | BTK 3747/4885ITK 4069/4885NTRK1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.